Evaluating BioNTech: Insights From 15 Financial Analysts
Portfolio Pulse from Benzinga Insights
In the past three months, 15 analysts have provided ratings for BioNTech (NASDAQ:BNTX), ranging from bullish to bearish. The average 12-month price target is $113.53, with a high of $171.00 and a low of $90.00. Recent ratings show a mix of 'Buy', 'Hold', and 'Neutral' stances, with some analysts lowering their price targets. BioNTech faces challenges with revenue growth, net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.
June 10, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioNTech has received mixed ratings from analysts, with an average price target of $113.53. The company faces significant challenges in revenue growth, net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.
The mixed analyst ratings and the average price target suggest a neutral short-term impact on BioNTech's stock price. The company's financial challenges are significant, but the low debt-to-equity ratio is a positive factor.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100